<DOC>
	<DOCNO>NCT00937651</DOCNO>
	<brief_summary>Study objective : 1 . To evaluate antihypertensive efficacy , safety tolerability drug oral administration BR-A-657•K 20~180mg 4 week patient essential hypertension . 2 . To review pharmacokinetic profile multiple administration pharmacodynamic profile regard renin-angiotensin system , oral administration BR-A-657•K 20~180mg 4 week patient essential hypertension . 3 . To determine dose clinical study next phase analyze relationship antihypertensive efficacy pharmacokinetic • pharmacodynamic result .</brief_summary>
	<brief_title>Efficacy , Safety Pharmacodynamic/Pharmacokinetic Study Fimasartan ( BR-A-657•K )</brief_title>
	<detailed_description>Fimasartan ( BR-A-657-K ) , selective blocker AT1 receptor subtype , show rapid potent antihypertensive effect many hypertensive model . Phase I study , Fimasartan ( BR-A-657-K ) 20mg ~ 480mg single dose healthy subject , demonstrate Fimasartan ( BR-A-657-K ) safe well tolerate . Another phase I study , Fimasartan ( BR-A-657-K ) 120mg 360mg dose 7 day , also show Fimasartan ( BR-A-657-K ) safe tolerable though one temporal adverse event observe high dose . A randomized , double-blind , placebo-controlled , parallel group , clinical study conduct evaluate antihypertensive efficacy tolerability determine adequate antihypertensive dosage Fimasartan ( BR-A-657-K ) patient mild moderate essential hypertension . Approximately 60 patient enrol 12 month Seoul National University Hospital . After 2 week placebo run-in period , subject randomize one follow 5 group . Subjects take test drug/placebo 28 day treatment period . If subject take antihypertensive medication screen , subject 1 week wash-out period . Group I : Placebo , Group II : Fimasartan 20 mg , Group III : Fimasartan 60 mg , Group IV : Fimasartan 180 mg</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<criteria>Adult men woman , age 18 65 Patients mild moderate essential hypertension : On screen Day 1 visit , mean sit DBP ≥ 95mmHg ≤ 114mmHg , ΔDBP Day 14 Day 1 within 7 mmHg Patients give consent participate study sign write informed consent form Patients understood study , judge cooperative able participate study study completion date 1 . Women childbearing potential receive hysterectomy men willing use birth control measure . 2 . Patients whose sit DBP &lt; 95mmHg ≥ 115mmHg . Patients severe hypertension whose SBP ≥200mmHg 3 . Patients secondary hypertension 4 . Patients severe renal disease , gastrointestinal disorder , hematologic disorder , liver disease , etc . affect absorption , distribution , metabolism excretion drug 5 . Patients symptoms orthostatic hypotension 6 . Patients severe insulin dependent diabetes uncontrolled diabetes 7 . Patients suffer myocardial infarction serious coronary arterial disease past 6 month patient clinically significant congestive heart failure valvular heart disease 8 . Patients consumption disease , autoimmune disease , connective tissue disease 9 . Patients history type B hepatitis type C hepatitis 10 . Patients HIV infection hepatitis 11 . Patients clinically significant abnormal laboratory test finding 12 . Patients drug treatment might affect blood pressure 13 . Patients allergy contraindication angiotensin IIreceptor antagonists 14 . Patients current suspect alcohol addiction history drug abuse 15 . Patients whose mean weight lie range 15 % ~ +35 % , base Modified Metropolitan Life Insurance table 16 . Patients eligible subject study , determine principal investigator subinvestigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Fimasartan</keyword>
	<keyword>Essential Hypertension</keyword>
</DOC>